翰宇药业拟定增募资不超9.68亿元，投向多肽药物产线及绿色智能化扩建等项目

Core Viewpoint - Han Yu Pharmaceutical plans to raise no more than 968 million yuan through a private placement of A-shares, aimed at addressing project investment and R&D funding needs, thereby alleviating financial pressure and enhancing risk resilience [1] Fundraising Details - The company intends to use the net proceeds from the fundraising for multiple projects, including the expansion of peptide drug production lines, green intelligent upgrades, peptide fragment production expansion, laboratory upgrades, and the development of Semaglutide [1] Financial Implications - The fundraising is expected to help the company manage its operational and R&D activities more effectively, ensuring a reasonable arrangement of resources and improving its ability to withstand financial risks [1]